JO3382B1 - أجسام مضادة ترتبط مع مستقبل cgrp بشري - Google Patents
أجسام مضادة ترتبط مع مستقبل cgrp بشريInfo
- Publication number
- JO3382B1 JO3382B1 JOP/2009/0461A JOP20090461A JO3382B1 JO 3382 B1 JO3382 B1 JO 3382B1 JO P20090461 A JOP20090461 A JO P20090461A JO 3382 B1 JO3382 B1 JO 3382B1
- Authority
- JO
- Jordan
- Prior art keywords
- cgrp
- receptor binding
- cgrp receptor
- binding antibodies
- human cgrp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
تقدم بروتينات مستضد الرابطة التي تربط بمستقبل جين كالسيتونين المرتبط بالبتيد CGRPR . كما تم توفير حموض نووية التي تشفر بروتين الرابطة للمستضد، ناقلات والخلايا التي تشفرها. يمكن تثبيط تشفير بروتين الرابطة للمستضد الرابط لمستقبل جين كالسيتونين المرتبط بالبتيد الى جين كالسيتونين المرتبط بالبتيد والتي تكون مفيدة في رقم مستقبل جين كالسيتونين المرتبط بالبتيد للاضطرابات المتعلقة، بما في ذلك معالجة و/او وقاية الصداع الشقي.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20356908P | 2008-12-23 | 2008-12-23 | |
US26462209P | 2009-11-25 | 2009-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3382B1 true JO3382B1 (ar) | 2019-03-13 |
Family
ID=41718325
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0461A JO3382B1 (ar) | 2008-12-23 | 2009-12-02 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
JOP/2019/0017A JOP20190017B1 (ar) | 2008-12-23 | 2019-02-07 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0017A JOP20190017B1 (ar) | 2008-12-23 | 2019-02-07 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
Country Status (40)
Country | Link |
---|---|
US (6) | US9102731B2 (ar) |
EP (3) | EP2379594B8 (ar) |
JP (6) | JP5761805B2 (ar) |
KR (4) | KR101740615B1 (ar) |
CN (2) | CN102348722B (ar) |
AR (1) | AR074857A1 (ar) |
AU (2) | AU2009330175C1 (ar) |
BR (2) | BR122020010360B1 (ar) |
CA (1) | CA2746858C (ar) |
CL (1) | CL2011001578A1 (ar) |
CO (1) | CO6400232A2 (ar) |
CR (1) | CR20110400A (ar) |
CY (3) | CY1119465T1 (ar) |
DK (2) | DK3184546T3 (ar) |
EA (2) | EA031320B1 (ar) |
ES (2) | ES2643835T3 (ar) |
HR (2) | HRP20171690T1 (ar) |
HU (3) | HUE045966T2 (ar) |
IL (2) | IL213429A (ar) |
JO (2) | JO3382B1 (ar) |
LT (3) | LT2379594T (ar) |
LU (1) | LUC00095I2 (ar) |
MA (1) | MA32982B1 (ar) |
ME (1) | ME03601B (ar) |
MX (1) | MX2011006804A (ar) |
MY (1) | MY180564A (ar) |
NL (1) | NL300961I2 (ar) |
NO (2) | NO2379594T3 (ar) |
NZ (2) | NZ606090A (ar) |
PE (1) | PE20120427A1 (ar) |
PL (2) | PL2379594T3 (ar) |
PT (2) | PT2379594T (ar) |
RS (2) | RS59343B1 (ar) |
SG (2) | SG10201401879TA (ar) |
SI (2) | SI2379594T1 (ar) |
TN (1) | TN2011000283A1 (ar) |
TW (4) | TW202241950A (ar) |
UA (1) | UA108066C2 (ar) |
WO (1) | WO2010075238A1 (ar) |
ZA (1) | ZA201105418B (ar) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2664421T3 (es) | 2005-11-14 | 2018-04-19 | Teva Pharmaceuticals International Gmbh | Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina |
WO2009070243A2 (en) * | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
US8293239B2 (en) | 2008-03-04 | 2012-10-23 | Pfizer Limited | Methods of treating chronic pain |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
WO2011024113A1 (en) | 2009-08-28 | 2011-03-03 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
CN103957935B (zh) | 2011-05-20 | 2018-04-03 | 奥尔德生物控股有限责任公司 | 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途 |
KR102098546B1 (ko) | 2011-05-20 | 2020-04-07 | 앨더바이오 홀딩스 엘엘씨 | 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도 |
CN108373502B (zh) | 2011-05-20 | 2022-03-22 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
AU2014236867A1 (en) * | 2013-03-15 | 2015-09-24 | Amgen Inc. | Methods and compositions relating to anti-CCR7 antigen binding proteins |
AP2015008732A0 (en) * | 2013-03-15 | 2015-09-30 | Amgen Inc | Human pac1 antibodies |
ES2943498T3 (es) | 2013-08-05 | 2023-06-13 | Twist Bioscience Corp | Genotecas sintetizadas de novo |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
JP7051293B2 (ja) | 2013-10-24 | 2022-04-11 | アムジエン・インコーポレーテツド | 温度感知制御を伴う薬剤送達システム |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
DK3119431T3 (da) * | 2014-03-21 | 2024-03-18 | Teva Pharmaceuticals Int Gmbh | Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf |
SG11201609219QA (en) | 2014-05-07 | 2016-12-29 | Amgen Inc | Autoinjector with shock reducing elements |
KR102506249B1 (ko) | 2014-06-03 | 2023-03-03 | 암겐 인코포레이티드 | 약물 전달 시스템 및 사용 방법 |
CA2960756C (en) | 2014-09-15 | 2023-08-01 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (ja) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | 近接センサ付き薬物送達装置 |
US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
ES2748750T3 (es) | 2015-02-17 | 2020-03-17 | Amgen Inc | Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
WO2016183479A1 (en) * | 2015-05-13 | 2016-11-17 | The Board Of Regents Of The University Of Oklahoma | Variants of adrenomedullin and calcitonin gene-related peptide and methods of use |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
GB2557529A (en) | 2015-09-18 | 2018-06-20 | Twist Bioscience Corp | Oligonucleic acid variant libraries and synthesis thereof |
WO2017053450A1 (en) | 2015-09-22 | 2017-03-30 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
CA3012827A1 (en) | 2016-02-02 | 2017-08-10 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
EP3721922B1 (en) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US10202435B2 (en) | 2016-04-15 | 2019-02-12 | Alder Biopharmaceuticals, Inc. | Anti-PACAP antibodies and uses thereof |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
WO2018057526A2 (en) | 2016-09-21 | 2018-03-29 | Twist Bioscience Corporation | Nucleic acid based data storage |
EA201990548A1 (ru) | 2016-09-23 | 2019-09-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Лечение кластерной головной боли |
EP3515937A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
JP2020514303A (ja) * | 2017-01-11 | 2020-05-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | R−スポンジン(rspo)サロゲート分子 |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
CA3050133A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
KR20190133174A (ko) * | 2017-03-02 | 2019-12-02 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 칼시토닌 유전자 관련 펩티드에 대해 지시되는 항체에 반응하는 두통 환자를 선택하는 방법 |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
CN110446512B (zh) | 2017-03-28 | 2022-03-18 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
CN111132711B (zh) | 2017-10-06 | 2022-07-01 | 安进公司 | 带有联锁组件的药物递送装置及相关组装方法 |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
KR20240024357A (ko) | 2017-10-20 | 2024-02-23 | 트위스트 바이오사이언스 코포레이션 | 폴리뉴클레오타이드 합성을 위한 가열된 나노웰 |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
MX2020006976A (es) | 2018-01-12 | 2020-10-05 | Amgen Inc | Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos. |
KR20200139720A (ko) | 2018-04-02 | 2020-12-14 | 암젠 인크 | 에레누맙 조성물 및 이의 용도 |
SG11202010100QA (en) | 2018-04-12 | 2020-11-27 | Amgen Inc | Methods for making stable protein compositions |
EP3814497A4 (en) | 2018-05-18 | 2022-03-02 | Twist Bioscience Corporation | POLYNUCLEOTIDES, REAGENTS, AND METHODS FOR NUCLEIC ACID HYBRIDIZATION |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
EP3826701A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
SG11202103800RA (en) | 2018-10-15 | 2021-05-28 | Amgen Inc | Drug delivery device having damping mechanism |
CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
WO2020092056A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial needle retraction |
US11639380B2 (en) * | 2019-01-08 | 2023-05-02 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
CA3131689A1 (en) * | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
CN114127110B (zh) * | 2019-05-30 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗cgrp抗体及其应用 |
CA3143524A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
WO2023215829A1 (en) * | 2022-05-05 | 2023-11-09 | Amgen Inc. | Heteromultimer binding dll3 and cd3 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH02229119A (ja) | 1989-02-28 | 1990-09-11 | Toyo Jozo Co Ltd | 動脈硬化予防および治療剤 |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0575319B1 (en) | 1991-03-11 | 1999-11-10 | The University Of Georgia Research Foundation, Inc. | Cloning and expression of renilla luciferase |
JPH06508035A (ja) | 1991-06-14 | 1994-09-14 | ディーエヌエックス コーポレーション | トランスジェニックブタにおけるヒトヘモグロビンの生産 |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
ES2131107T3 (es) * | 1992-03-17 | 1999-07-16 | Novartis Ag | Anticuerpos obtenidos mediante ingenieria genetica. |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5766880A (en) * | 1992-10-27 | 1998-06-16 | Queen's University At Kingston | Isolated nucleic acid molecules encoding multidrug resistance proteins |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
AU694745B2 (en) | 1993-09-10 | 1998-07-30 | Trustees Of Columbia University In The City Of New York, The | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
WO1996003993A2 (en) | 1994-08-05 | 1996-02-15 | The Rockefeller University | Modulation of thymocyte and t cell functional activity |
AU7953194A (en) * | 1994-08-16 | 1996-03-07 | Human Genome Sciences, Inc. | Calcitonin receptor |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
WO1998026277A2 (en) | 1996-12-12 | 1998-06-18 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
DE19732944A1 (de) | 1997-07-31 | 1999-02-04 | Thomae Gmbh Dr K | Peptidische CGRP-Antagonisten |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
EP1064360B1 (en) | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics |
US6268474B1 (en) | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
WO2001040794A1 (en) * | 1999-12-02 | 2001-06-07 | Myriad Genetics, Inc. | Protein-protein interactions |
US20020090646A1 (en) | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
FR2821080B1 (fr) | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques |
IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2003027252A2 (en) * | 2001-09-27 | 2003-04-03 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7494804B2 (en) * | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
US20040110170A1 (en) * | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
BR0313388A (pt) * | 2002-08-12 | 2005-07-05 | Birkir Sveinsson | Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase |
US20040176577A1 (en) * | 2002-09-10 | 2004-09-09 | Eva Rojer | Immunoassays for specific determination of SCCA isoforms |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
AU2005319382B2 (en) * | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
JP4993606B2 (ja) | 2005-06-16 | 2012-08-08 | 隆行 新藤 | Ramp2を標的とする血管構造の安定化剤及び血管新生剤 |
GB0521139D0 (en) * | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
ES2664421T3 (es) | 2005-11-14 | 2018-04-19 | Teva Pharmaceuticals International Gmbh | Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina |
WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
CN101553505B (zh) * | 2006-08-03 | 2013-07-17 | 阿斯利康(瑞典)有限公司 | 针对αVβ6的抗体及其应用 |
GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
ES2584907T3 (es) | 2008-03-04 | 2016-09-30 | Labrys Biologics Inc. | Métodos para tratamiento del dolor inflamatorio |
FR2934597B1 (fr) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
WO2011024113A1 (en) | 2009-08-28 | 2011-03-03 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
CA2960756C (en) * | 2014-09-15 | 2023-08-01 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
US11385238B2 (en) * | 2017-06-30 | 2022-07-12 | Amgen Inc. | Methods of protein clips recovery |
KR20200139720A (ko) * | 2018-04-02 | 2020-12-14 | 암젠 인크 | 에레누맙 조성물 및 이의 용도 |
-
2009
- 2009-12-02 JO JOP/2009/0461A patent/JO3382B1/ar active
- 2009-12-18 EA EA201100892A patent/EA031320B1/ru active Protection Beyond IP Right Term
- 2009-12-18 HU HUE16199717A patent/HUE045966T2/hu unknown
- 2009-12-18 NZ NZ606090A patent/NZ606090A/en unknown
- 2009-12-18 EA EA201891500A patent/EA201891500A3/ru unknown
- 2009-12-18 US US12/642,711 patent/US9102731B2/en active Active
- 2009-12-18 LT LTEP09775072.3T patent/LT2379594T/lt unknown
- 2009-12-18 BR BR122020010360-4A patent/BR122020010360B1/pt active IP Right Grant
- 2009-12-18 UA UAA201109219A patent/UA108066C2/ru unknown
- 2009-12-18 PT PT97750723T patent/PT2379594T/pt unknown
- 2009-12-18 PE PE2011001269A patent/PE20120427A1/es active IP Right Grant
- 2009-12-18 RS RSP20191122 patent/RS59343B1/sr unknown
- 2009-12-18 PL PL09775072T patent/PL2379594T3/pl unknown
- 2009-12-18 RS RS20171121A patent/RS56567B1/sr unknown
- 2009-12-18 CN CN200980157606.3A patent/CN102348722B/zh active Active
- 2009-12-18 KR KR1020117017235A patent/KR101740615B1/ko active IP Right Grant
- 2009-12-18 KR KR1020177013822A patent/KR101853393B1/ko active IP Right Grant
- 2009-12-18 WO PCT/US2009/068858 patent/WO2010075238A1/en active Application Filing
- 2009-12-18 JP JP2011543606A patent/JP5761805B2/ja active Active
- 2009-12-18 MY MYPI2011002908A patent/MY180564A/en unknown
- 2009-12-18 SG SG10201401879TA patent/SG10201401879TA/en unknown
- 2009-12-18 MX MX2011006804A patent/MX2011006804A/es active IP Right Grant
- 2009-12-18 DK DK16199717.6T patent/DK3184546T3/da active
- 2009-12-18 PT PT16199717T patent/PT3184546T/pt unknown
- 2009-12-18 AU AU2009330175A patent/AU2009330175C1/en active Active
- 2009-12-18 EP EP09775072.3A patent/EP2379594B8/en active Active
- 2009-12-18 EP EP16199717.6A patent/EP3184546B8/en active Active
- 2009-12-18 NZ NZ623541A patent/NZ623541A/en unknown
- 2009-12-18 DK DK09775072.3T patent/DK2379594T3/en active
- 2009-12-18 NO NO09775072A patent/NO2379594T3/no unknown
- 2009-12-18 CN CN201610333096.2A patent/CN106084045B/zh active Active
- 2009-12-18 SI SI200931756T patent/SI2379594T1/sl unknown
- 2009-12-18 PL PL16199717T patent/PL3184546T3/pl unknown
- 2009-12-18 HU HUE09775072A patent/HUE034506T2/en unknown
- 2009-12-18 ES ES09775072.3T patent/ES2643835T3/es active Active
- 2009-12-18 ME MEP-2019-240A patent/ME03601B/me unknown
- 2009-12-18 LT LTEP16199717.6T patent/LT3184546T/lt unknown
- 2009-12-18 BR BRPI0922505-6A patent/BRPI0922505B1/pt active IP Right Grant
- 2009-12-18 KR KR1020197013698A patent/KR20190054181A/ko not_active Application Discontinuation
- 2009-12-18 MA MA34035A patent/MA32982B1/ar unknown
- 2009-12-18 SG SG2011045556A patent/SG172307A1/en unknown
- 2009-12-18 ES ES16199717T patent/ES2746571T3/es active Active
- 2009-12-18 CA CA2746858A patent/CA2746858C/en active Active
- 2009-12-18 EP EP19181187.6A patent/EP3569620A1/en active Pending
- 2009-12-18 SI SI200931989T patent/SI3184546T1/sl unknown
- 2009-12-18 KR KR1020187011418A patent/KR20180043850A/ko active Application Filing
- 2009-12-22 TW TW110149087A patent/TW202241950A/zh unknown
- 2009-12-22 AR ARP090105053A patent/AR074857A1/es active IP Right Grant
- 2009-12-22 TW TW098144377A patent/TWI574697B/zh active
- 2009-12-22 TW TW105134382A patent/TWI688403B/zh active
- 2009-12-22 TW TW108136419A patent/TWI754176B/zh active
-
2011
- 2011-06-01 TN TN2011000283A patent/TN2011000283A1/fr unknown
- 2011-06-06 IL IL213429A patent/IL213429A/en active Protection Beyond IP Right Term
- 2011-06-23 CL CL2011001578A patent/CL2011001578A1/es unknown
- 2011-07-15 CO CO11088995A patent/CO6400232A2/es active IP Right Grant
- 2011-07-22 CR CR20110400A patent/CR20110400A/es unknown
- 2011-07-22 ZA ZA2011/05418A patent/ZA201105418B/en unknown
-
2012
- 2012-09-12 US US13/612,615 patent/US20130071410A1/en not_active Abandoned
-
2013
- 2013-04-10 AU AU2013205271A patent/AU2013205271C1/en active Active
-
2014
- 2014-08-12 JP JP2014164088A patent/JP6261132B2/ja active Active
-
2015
- 2015-06-26 US US14/752,493 patent/US9862771B2/en active Active
- 2015-11-09 JP JP2015219157A patent/JP2016026224A/ja not_active Withdrawn
-
2016
- 2016-01-26 IL IL243784A patent/IL243784A/en active IP Right Grant
-
2017
- 2017-08-28 CY CY20171100901T patent/CY1119465T1/el unknown
- 2017-11-06 HR HRP20171690TT patent/HRP20171690T1/hr unknown
- 2017-11-28 US US15/824,827 patent/US20180142029A1/en not_active Abandoned
-
2018
- 2018-12-04 CY CY2018032C patent/CY2018032I2/el unknown
- 2018-12-10 HU HUS1800047C patent/HUS1800047I1/hu unknown
- 2018-12-12 NL NL300961C patent/NL300961I2/nl unknown
- 2018-12-14 LT LTPA2018017C patent/LTC2379594I2/lt unknown
- 2018-12-17 NO NO2018042C patent/NO2018042I1/no unknown
- 2018-12-20 LU LU00095C patent/LUC00095I2/fr unknown
- 2018-12-28 JP JP2018246704A patent/JP2019062907A/ja not_active Withdrawn
-
2019
- 2019-02-07 JO JOP/2019/0017A patent/JOP20190017B1/ar active
- 2019-07-25 HR HRP20191341TT patent/HRP20191341T8/hr unknown
- 2019-09-19 CY CY20191100989T patent/CY1122658T1/el unknown
-
2020
- 2020-11-27 JP JP2020196689A patent/JP2021036912A/ja active Pending
- 2020-12-03 US US17/111,442 patent/US20210179722A1/en active Pending
- 2020-12-03 US US17/111,453 patent/US20210179723A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101810A patent/JP2023116783A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20190017B1 (ar) | أجسام مضادة ترتبط مع مستقبل cgrp بشري | |
MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
PH12014502527A1 (en) | St2 antigen binding proteins | |
EA201001223A1 (ru) | Стабилизированные белковые композиции | |
NZ583282A (en) | Human c-fms antigen binding proteins | |
MX2012012927A (es) | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
WO2010019570A3 (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
NZ593905A (en) | Il-1 binding proteins | |
MY160590A (en) | Cd127 binding proteins | |
MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
EA201290630A1 (ru) | Лечение расстройства обмена веществ | |
UA100531C2 (ru) | Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp) | |
UA97414C2 (ru) | Выделенное человеческое антитело, связывающееся с gm-csf |